<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03536104</url>
  </required_header>
  <id_info>
    <org_study_id>2008_0811</org_study_id>
    <secondary_id>2008-A00219-46</secondary_id>
    <nct_id>NCT03536104</nct_id>
  </id_info>
  <brief_title>Identification of Risk Factors Parkinson's Disease by Convergence Strategy</brief_title>
  <acronym>CONVERGENCE</acronym>
  <official_title>Identification of Risk Factors Parkinson's Disease by Convergence Strategy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Lille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Lille</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Using this convergence approach from a limited group of subjects with non-diseased controls,&#xD;
      patients with Parkinson's disease or related diseases, we will be able to limit the number of&#xD;
      potential genes of specific susceptibility to Parkinson disease. These genes will then be&#xD;
      studied using a case-control genetic epidemiology approach. The risk of developing the&#xD;
      disease will then be evaluated according to clinical, biological and environmental variables&#xD;
      collected in Parkinson's subjects and healthy controls in the second group of subjects. The&#xD;
      specificity of the genetic associations found will be evaluated in subjects with Parkinson's&#xD;
      disease.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 25, 2009</start_date>
  <completion_date type="Anticipated">March 2024</completion_date>
  <primary_completion_date type="Anticipated">March 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Significant variations in the frequencies of gene polymorphisms and the risk of developing Parkinson's disease</measure>
    <time_frame>through study completion, an average of 10 years</time_frame>
    <description>the frequency is measured according to biological and environmental variables modulating the risk of developing Parkinson's disease.</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">2220</enrollment>
  <condition>Parkinson Disease</condition>
  <arm_group>
    <arm_group_label>Controls</arm_group_label>
    <description>This group will include &quot;healthy&quot; person.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Parkinson's patient</arm_group_label>
    <description>This group will include Parkinsonian patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>patients with a related disease.</arm_group_label>
    <description>This group will include patients with a related disease.</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      serum, plasma, CSF&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with Parkinson Disease compared to subjects at risk to develop Parkinson Disease&#xD;
        and healthy controls&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Inclusion criteria for Parkinson's patients and &quot;related diseases&quot; controls:&#xD;
&#xD;
          -  Parkinsonian patients meeting the Gelb criteria&#xD;
&#xD;
          -  Patients with other neurodegenerative disease (such as other Parkinson syndrome or&#xD;
             synucleopathies) meeting the criteria set out in Appendix 2 (Lewy Bodies dementia,&#xD;
             Parkinson's disease with dementia, MultiSystem atrophy, Progressive Supranuclear&#xD;
             Paralysis) , Amyotrophic Lateral Sclerosis, Restless Legs Syndrome, Alzheimer's&#xD;
             Disease).&#xD;
&#xD;
          -  Woman of childbearing age having an effective means of contraception.&#xD;
&#xD;
          -  Informed consent signed by the subject or his legal representative.&#xD;
&#xD;
          -  For demented subjects coming for consultation or day hospitalization with an&#xD;
             accompanying person, signature of the legal representative.&#xD;
&#xD;
        Criteria for inclusion of non-ill controls:&#xD;
&#xD;
          -  Absence of rest trembling, bradykinesia and stiffness&#xD;
&#xD;
          -  MMSE (Mini Mental State Examination) greater than 25&#xD;
&#xD;
          -  Woman of childbearing age having an effective means of contraception.&#xD;
&#xD;
          -  subject having signed the informed consent.&#xD;
&#xD;
          -  No family history of neurodegenerative disease that started before age 70. These&#xD;
             controls will not present any Parkinsonian signs during the clinical evaluation. They&#xD;
             may have functional disabilities whose cause is known and unrelated to a&#xD;
             neurodegenerative disease with a cognitive function measurement greater than 25 in the&#xD;
             MMSE test.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Criteria for non-inclusion of patients:&#xD;
&#xD;
          -  Clinical criteria for exclusion of the diseases described&#xD;
&#xD;
          -  Participation in another therapeutic trial or in the exclusion period of a previous&#xD;
             clinical trial.&#xD;
&#xD;
        Criteria for non-inclusion of non-ill controls:&#xD;
&#xD;
          -  Functional discomfort in daily life of unknown cause&#xD;
&#xD;
          -  MMSE less than 25&#xD;
&#xD;
          -  Participation in another therapeutic trial or in the exclusion period of a previous&#xD;
             clinical trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alain DESTEE, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Lille</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alain DESTEE, MD,PhD</last_name>
    <email>alain.destee@chru-lille.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>HÃ´pital Roger Salengro, CHRU de Lille</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Alain DESTEE, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>May 14, 2018</study_first_submitted>
  <study_first_submitted_qc>May 14, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 24, 2018</study_first_posted>
  <last_update_submitted>August 24, 2020</last_update_submitted>
  <last_update_submitted_qc>August 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

